INDIANAPOLIS, Sept. 10, 2024. Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin...
Vous n'êtes pas connecté
INDIANAPOLIS, Sept. 10, 2024. Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using...
INDIANAPOLIS, Sept. 10, 2024. Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin...
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
FRIDAY, Sept. 13, 2024 -- Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2...
WEDNESDAY, Sept. 11, 2024 -- Weekly insulin shots can help control both type 1 and type 2 diabetes as well as daily injections do, a pair of clinical...
NEW YORK, Sept. 5 (Xinhua) -- U.S. drugmaker Eli Lilly announced more progress toward a once-weekly insulin shot, weeks after its Danish competitor...
NEW YORK, Sept. 5 (Xinhua) -- U.S. drugmaker Eli Lilly announced more progress toward a once-weekly insulin shot, weeks after its Danish competitor...
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
Diabetes affects over 37 million people in the U.S., with many of them living with type 2 diabetes. This form of diabetes used to be most common among...
Diabetes affects over 37 million people in the U.S., with many of them living with type 2 diabetes. This form of diabetes used to be most common among...